Melanoma Cell Death Mechanisms

다국어 초록 (Multilingual Abstract)

Over recent years, several new molecular and immunogenic therapeutic approaches to melanoma treatment have been approved and implemented in clinical practice. Mechanisms of resistance to these new therapies have become a major problem. Mutation-specific pharmacotherapy can result in simultaneous emergence of resistant clones at many separate body sites despite an initially positive therapeutic response. Additionally, treatments aimed at inducing apoptosis are subject to resistance due to escape through other known mechanisms of regulated cell death (RCD). In this review, we discuss the complexity in pharmacological manipulation of melanoma with c-Kit, BRAF, MEK, and/or mTOR mutant cell lines. This study also addresses melanoma evasion of cell death through modalities of RCD such as apoptosis, autophagy, and necroptosis. This study also examines new combination therapies which have been approved to target both cell cycle dysregulation and cell death pathways. Lastly, we recognize the importance of immunomodulation though manipulation of the body’s natural killing mechanisms with CTLA4, PD1, and CSF1 inhibition. As we begin to recognize tumor cell activation of alternate pathways, evasion of programmed cell death, and manipulation of the tumor microenvironment, it is increasingly important to grasp the complexity of personalized therapy in melanoma treatment.

참고문헌 (Reference)

1 Hayward NK, "Whole-genome landscapes of major melanoma subtypes" 545 : 175-180, 2017

2 Caldarola G, "Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL): a possible pathogenic role in chronic plaque psoriasis" 151 : 17-24, 2016

3 Lugowska I, "Trametinib: a MEK inhibitor for management of metastatic melanoma" 8 : 2251-2259, 2015

4 Cheng Y, "Therapeutic targeting of autophagy in disease: biology and pharmacology" 65 : 1162-1197, 2013

5 류순효, "Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma" 의과학연구소 53 (53): 173-177, 2017

6 Whiteman DC, "The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031" 136 : 1161-1171, 2016

7 Wang Y, "Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines" 104 : 643-652, 2011

8 Carvajal RD, "Targeting KIT for treatment of advanced melanoma" 29 : 2011

9 Neubert NJ, "T cell-induced CSF1 promotes melanoma resistance to PD1 blockade" 10 : eaan3311-, 2018

10 Boni A, "Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function" 70 : 5213-5219, 2010

11 Manzano JL, "Resistant mechanisms to BRAF inhibitors in melanoma" 4 : 237-, 2016

12 Welsh SJ, "Resistance to combination BRAF and MEK inhibition in metastatic melanoma: where to next?" 62 : 76-85, 2016

13 Adewale FO, "Regulation of apoptotic and necroptotic cell death in skin cancer" 5 : 1108-1117, 2017

14 Kim DW, "Profile of selumetinib and its potential in the treatment of melanoma" 7 : 1631-1639, 2014

15 Guo J, "Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification" 29 : 2904-2909, 2011

16 Vera Aguilera J, "Phase II study of Everolimus in metastatic malignant melanoma (NCCTG-N0377, alliance)" 23 : 887-e894, 2018

17 Avery-Kiejda KA, "P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation" 11 : 203-, 2011

18 Kaczmarek A, "Necroptosis: the release of damage-associated molecular patterns and its physiological relevance" 38 : 209-223, 2013

19 Cheng L, "Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine" 31 : 24-38, 2018

20 Galluzzi L, "Molecular mechanisms of cell death: recommendations of the nomenclature committee on Cell death 2018" 25 : 486-541, 2018

21 Gounder MM, "Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor" 67 (67): S25-S43, 2011

22 Smalley KS, "Melanoma--an unlikely poster child for personalized cancer therapy" 363 : 876-878, 2010

23 Karbowniczek M, "MTOR is activated in the majority of malignant melanomas" 128 : 980-987, 2008

24 Vucic D, "ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas" 10 : 1359-1366, 2000

25 Grimaldi AM, "MEK inhibitors in the treatment of metastatic melanoma and solid tumors" 18 : 745-754, 2017

26 Egger ME, "Inhibition of autophagy with chloroquine is effective in melanoma" 184 : 274-281, 2013

27 Hodi FS, "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin" 31 : 3182-3190, 2013

28 Moon KR, "Genetic alterations in primary acral melanoma and acral melanocytic nevus in Korea: common mutated genes show distinct cytomorphological features" 138 : 933-945, 2018

29 Amann VC, "Developments in targeted therapy in melanoma" 43 : 581-593, 2017

30 Long GV, "Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial" 386 : 444-451, 2015

31 Xie X, "Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma" 8 : e55096-, 2013

32 "Cobimetinib for metastatic melanoma" 40 : 30-31, 2017

33 Karlsson AK, "Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis" 10 : 325-339, 2017

34 Mattia G, "Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies" 9 : 112-, 2018

35 Glick D, "Autophagy: cellular and molecular mechanisms" 221 : 3-12, 2010

36 Duffy A, "Autophagy modulation: a target for cancer treatment development" 75 : 439-447, 2015

37 Wong RS, "Apoptosis in cancer: from pathogenesis to treatment" 30 : 87-, 2011

38 Hirayama Y, "Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma" 107 : 1736-1744, 2016

39 Kong Y, "Analysis of mTOR gene aberrations in melanoma patients and evaluation of their sensitivity to PI3K-AKT-mTOR pathway inhibitors" 22 : 1018-1027, 2016

40 Geserick P, "Absence of RIPK3 predicts necroptosis resistance in malignant melanoma" 6 : e1884-, 2015